Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
| Drug | Cmax* % Improvement (ng/mL) | Control (ng/mL) | AUClast** % Improvement (hr∙ng/mL) | Control (hr∙ng/mL) |
| Colchicine | 31.97 91% (p=0.0005) | 16.73 | 104.43 167% (p=0.0028) | 38.97 |
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.